Company news

Esperion Therapeutics, Inc. news in 2026

Esperion Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Esperion Therapeutics Offers Short-Term Option for Diuretic Management Before Escalation to IV for Patients With Heart Failure

September 30, 2026

Esperion Presents New Data from CLEAR Outcomes and the CLEAR PATH Phase 2 Pediatric Study at the European Atherosclerosis Society Congress 2026

May 26, 2026

Esperion Announces Two New Analyses Supporting Bempedoic Acid to Reduce LDL-C Levels to be Presented at the European Atherosclerosis Society (EAS) Congress 2026

May 13, 2026

Esperion to be Acquired by ARCHIMED

May 1, 2026

Esperion to Report First Quarter 2026 Financial Results on May 7

April 23, 2026

Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

April 1, 2026

Athyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing to Support Strategic Acquisition of Corstasis Therapeutics

April 1, 2026

Esperion to Participate in 25th Annual Needham Virtual Healthcare Conference

March 30, 2026

Esperion Showcases New Data from CLEAR Outcomes Highlighting Value of NEXLETOL® (bempedoic acid) at the American College of Cardiology’s Annual Scientific Session 2026

March 29, 2026

Esperion to Present Two New Analyses from CLEAR Outcomes Clinical Trial at the American College of Cardiology 2026 Annual Scientific Session

March 16, 2026

Esperion’s Bempedoic Acid Receives Multiple Class 1 Recommendations in 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia

March 15, 2026

Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

March 9, 2026

Correction: HLS Therapeutics Inc.

March 5, 2026

Esperion Therapeutics and Corstasis Therapeutics Announce Esperion's Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst

March 4, 2026

Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

March 2, 2026

Esperion to Report Fourth Quarter and Full Year 2025 Financial Results on March 10

February 23, 2026

Esperion to Participate in The 2026 Citizens Life Sciences Conference

February 17, 2026

Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bempedoic acid & ezetimibe) Prior to April 19, 2040

February 17, 2026

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

February 11, 2026

Esperion Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference

January 11, 2026

Esperion to Participate in Upcoming 44th Annual J.P. Morgan Healthcare Conference

January 5, 2026

Calls in 2026

Decks in 2026